Please use this identifier to cite or link to this item:
Title: CB2 cannabinoid receptor as potential target against alzheimer's disease
Author: Aso Pérez, Ester
Ferrer, Isidro (Ferrer Abizanda)
Keywords: Cànnabis
Malaltia d'Alzheimer
Estrès oxidatiu
Alzheimer's disease
Oxidative stress
Issue Date: May-2016
Publisher: Frontiers Media
Abstract: The CB2 receptor is one of the components of the endogenous cannabinoid system, a complex network of signaling molecules and receptors involved in the homeostatic control of several physiological functions. Accumulated evidence suggests a role for CB2 receptors in Alzheimer's disease (AD) and indicates their potential as a therapeutic target against this neurodegenerative disease. Levels of CB2 receptors are significantly increased in post-mortem AD brains, mainly in microglia surrounding senile plaques, and their expression levels correlate with the amounts of Aβ42 and β-amyloid plaque deposition. Moreover, several studies on animal models of AD have demonstrated that specific CB2 receptor agonists, which are devoid of psychoactive effects, reduce AD-like pathology, resulting in attenuation of the inflammation associated with the disease but also modulating Aβ and tau aberrant processing, among other effects. CB2 receptor activation also improves cognitive impairment in animal models of AD. This review discusses available data regarding the role of CB2 receptors in AD and the potential usefulness of specific agonists of these receptors against AD.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Neuroscience, 2016, vol. 31, num. 10, p. 243
Related resource:
ISSN: 1662-4548
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
667088.pdf636.75 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons